Madagascar vs Papua New Guinea: Antiretroviral therapy coverage for PMTCT
Madagascar
30.0%
in 2024
Papua New Guinea
28.0%
in 2024
Madagascar rank
77th
Papua New Guinea rank
78th
Antiretroviral therapy coverage for PMTCT over time
- Madagascar
- Papua New Guinea
How they compare
Madagascar currently reports 30.0% against 28.0% in Papua New Guinea, a difference of 2.0%.
That makes Madagascar's figure about 1.1 times Papua New Guinea's.
The two have swapped places 7 times across 25 shared years of data; in 2000 it was Papua New Guinea ahead.
Madagascar ranks 77th and Papua New Guinea ranks 78th of 84 countries.
Across the 3 decades both report, Madagascar averaged higher in 2 and Papua New Guinea in 1.
Head to head by decade
| Decade | Madagascar | Papua New Guinea | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 1.1% | 0.7% | 0.4% | Madagascar |
| 2010s | 7.8% | 10.9% | 3.1% | Papua New Guinea |
| 2020s | 21.4% | 20.6% | 0.8% | Madagascar |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher antiretroviral therapy coverage for pmtct, Madagascar or Papua New Guinea?
- Madagascar, at 30.0% against 28.0% in Papua New Guinea as of 2024.
- What is the difference in antiretroviral therapy coverage for pmtct between Madagascar and Papua New Guinea?
- 2.0%, with Madagascar ahead.
- How many years of comparable data are there for Madagascar and Papua New Guinea?
- 25 years are reported by both, from 2000 to 2024.
- How do Madagascar and Papua New Guinea rank globally for antiretroviral therapy coverage for pmtct?
- Madagascar ranks 77th and Papua New Guinea ranks 78th of 84 countries.
- Where does this data come from?
- UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of pregnant women with HIV who receive antiretroviral medicine for prevention of mother-to-child transmission (PMTCT).